Gayer, who took the top job in January, said Orladeyo, BioCryst’s once-daily pill for hereditary angioedema, is generating the money to fund a new drug buy. ・BioCryst expects full-year Orladeyo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results